Top-News

PTC Therapeutics Aktie News

Aktie
WKN:  A1W0MW ISIN:  US69366J2006 US-Symbol:  PTCT Branche:  Biotechnologie Land:  USA
67,00 €
-0,50 €
-0,74%
13:14:14 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-9,58
Index-Zuordnung
-

PTC Therapeutics News

01.12.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.11.25 - PR Newswire
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600 PR Newswire
20.11.25 - PR Newswire
PTC Therapeutics to Host R&D Day
PTC Therapeutics to Host R&D Day PR Newswire
04.11.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results PR Newswire
31.10.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
27.10.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
21.10.25 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results PR Newswire
01.10.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
04.09.25 - wallstreetONLINE Redaktion
Favoritenliste: JPMorgan kürt neue Favoriten: Diese Aktien haben im September großes Potenzial
JPMorgan hat seine Favoritenliste für September neu aufgestellt. Mit dabei sind PTC Therapeutics, Armstrong World Industries und McCormick. Die Hintergründe. Die Analysten von ...
21.08.25 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
19.08.25 - PR Newswire
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA PR Newswire
07.08.25 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results PR Newswire
28.07.25 - PR Newswire
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
21.07.25 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results PR Newswire
24.06.25 - PR Newswire
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire
23.06.25 - PR Newswire
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
19.06.25 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »